TGM2 and hepatocellular carcinoma: In contrast, two independent clinical studies showed that the tissue and/or serum TG2 expression were significantly increased in patients with early stage HCC whose with no evaluated level of AFP [44] or with early recurrence within 12 months after primary treatment [45].